Medincell: UZEDY's 25% Revenue Boost Drives 2024 Outlook

Medincell, a clinical- and commercial-stage biopharmaceutical licensing company, has recently announced a significant 25% raise in its 2024 revenue outlook for UZEDY®. This positive update reflects the strong market performance of UZEDY®, a long-acting injectable antipsychotic medication for schizophrenia, and highlights the potential for substantial growth in the coming years.

UZEDY®, based on Medincell's proprietary BEPO® technology, was approved by the U.S. FDA in April 2023 and launched commercially by Teva Pharmaceuticals in May 2023. The drug's positive market reception and adoption have led to impressive revenue growth, with U.S. revenues year-to-date reaching $75 million and Q3 2024 revenues totaling $35 million. This strong performance has resulted in an updated 2024 revenue outlook of $100 million for UZEDY®, up from the previous projection of $80 million.

Medincell's partnership with Teva Pharmaceuticals has been instrumental in driving UZEDY®'s success. Teva, a global leader in generics and a prominent player in specialty medicines, has fully embraced the commercialization of UZEDY®. The company's confidence in the drug's potential is evident in its Q3 2024 results, which indicate a strong uptake and significant growth for UZEDY® in 2024.


The progress of Medincell's Olanzapine Long-Acting Injectable (LAI) clinical trials has also contributed to the company's positive outlook. The completion of 100% of targeted injections for submission without Post-Injection Delirium/Sedation Syndrome (PDSS) is a major milestone that enhances the safety profile and market potential of the drug. This success, combined with Teva's strong Q3 2024 results, has further bolstered Medincell's confidence in UZEDY®'s growth prospects.


Medincell's innovative BEPO® technology, which controls the delivery of a drug at a therapeutic level for several days, weeks, or months, has proven to be a valuable asset in the development of long-acting injectable drugs. The company's ability to create breakthrough products, as demonstrated by UZEDY® and its Olanzapine LAI, positions Medincell competitively in the long-acting injectable antipsychotic market.

In conclusion, Medincell's 25% raise in the 2024 UZEDY® revenue outlook reflects the strong market performance and potential of the drug. The company's strategic partnership with Teva Pharmaceuticals, combined with the successful progress of its Olanzapine LAI clinical trials, has contributed to this positive outlook. As Medincell continues to innovate and develop new products, investors can expect the company to maintain its competitive edge in the long-acting injectable antipsychotic market.